All IndicationsImmunology & InflammationPhase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 2
🛡️
Psoriasis
5
Companies
10
Drug Programs
6
Phase 3
0
Upcoming PDUFAs
Competitors
LLY
Eli Lilly and Company
Ixekizumab
TAK
Takeda
zasocitinib
TAK
Takeda
PsO pill
AUPH
Aurinia Pharmaceuticals Inc.
Ciclosporin
LLY
Eli Lilly and Company
80 mg ixekizumab
AUPH
Aurinia Pharmaceuticals Inc.
Placebo
INCY
Incyte Corporation
Ruxolitinib phosphate cream
LLY
Eli Lilly and Company
ixekizumab
ABBV
AbbVie
Skyrizi
TAK
Takeda Pharmaceutical
Zasocitinib
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Ixekizumab | Phase 3 | — | — | — |
| TAK Takeda | zasocitinib | Phase 3 | — | — | — |
| TAK Takeda | PsO pill | Phase 3 | — | — | — |
| AUPH Aurinia Pharmaceuticals Inc. | Ciclosporin | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | 80 mg ixekizumab | Phase 3 | — | — | — |
| AUPH Aurinia Pharmaceuticals Inc. | Placebo | Phase 3 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib phosphate cream | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | ixekizumab | — | — | — | — |
| ABBV AbbVie | Skyrizi | — | — | — | — |
| TAK Takeda Pharmaceutical | Zasocitinib | — | — | — | — |
Development Stage Distribution
Unknown
3
Phase 3
6
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.